

Wellnex delivers *Pharmacy Own* products to joint venture partner CH2

Highlights:

- Wellnex Life has delivered the first [Pharmacy Own](#) products to joint venture partner [CH2](#).
- CH2 will distribute *Pharmacy Own* products through their extensive distribution network in the healthcare industry.
- The *Pharmacy Own* brand is wholly owned by Wellnex and is expected to result in significant sales and margin enhancement, with further product launches planned through 2023.

Wellnex Life Limited (ASX: WNX), customer-focused health and wellness company, is pleased to announce the delivery of the first *Pharmacy Own* products to CH2. The *Pharmacy Own* brand is wholly owned by Wellnex and is expected to deliver significant sales and enhanced margins to the wider group. Wellnex continues to expand its portfolio of innovative health and wellness products to meet growing consumer demand.

CH2 (Clifford Hallam Healthcare) is Australia's only fully integrated pharmaceutical and medical consumable distributor with an extensive network that includes over 2,500 pharmacies. In a joint venture with Wellnex, CH2 will be the exclusive distributor of *Pharmacy Own* products through their distribution network. The joint venture with CH2 will allow Wellnex to gain immediate national distribution across CH2's extensive network, with Wellnex retaining 100% ownership of the *Pharmacy Own* brand.

About *Pharmacy Own*

The *Pharmacy Own* brand consists of a range of high-quality, affordable over-the-counter (OTC) medicines that will provide consumers equivalent efficacious products to the major brands currently found in the Australian market. Both consumers and pharmacies will benefit from competitive retail prices of the products. Wellnex is targeting the launch of up to 20 core *Pharmacy Own* products in the first 12 months, expanding to over 50 products in the long term, across categories including cough and cold, hay fever, pain relief and vitamins.





About [Clifford Hallam Healthcare \(CH2\)](#)

CH2 is Australia's leading integrated distributor of pharmaceuticals, medical consumables, nutritional and equipment servicing the healthcare market. CH2 has a portfolio of over 50,000 products from over 700 recognised suppliers and service the entire healthcare market across hospital, pharmacy, primary, aged and community care and contract logistics.

George Karafotias, CEO of Wellnex Life, said: "Wellnex is excited to bring to market another innovative brand in *Pharmacy Own* that will meet the growing demand for affordable over-the-counter medicines. Partnering up with CH2 on this launch will see *Pharmacy Own* products distributed across a large and established distribution network that will maximise sales for Wellnex whilst also keeping costs down for consumers."

This announcement has been authorised for release on the ASX by the Company's Board of Directors.

ENDS

Further Information:

Wellnex Life

George Karafotias
Chief Executive Officer
Email: george.k@wellnexlife.com.au
Phone: 03 8399 9419

Investor & Media Relations

Sophie Bradley
Investor Relations Executive
Email: IR@reachmarkets.com.au
Phone: 1300 805 795

About Wellnex Life:

Wellnex Life (ASX: WNX) is an Australian brand and distribution company of customer-focused health and wellness products. The company's large portfolio, first-to-market strategy and established retail distribution network provide an attractive business model for growth and profitability. Wellnex's mission is to deliver health, wellness, and vitality solutions to consumers in Australia and worldwide.

To stay up to date with Wellnex Life news and announcements, register your details on the [Wellnex Life investor portal](#).